PCSK9 siRNA
PCSK9 small interfering RNA (siRNA)
- Silences hepatic PCSK9 messenger RNA before protein production
- Less PCSK9 → more LDL receptors recycled to the hepatocyte surface → lower LDL-C
- Durable silencing → infrequent dosing
- GalNAc conjugation targets the hepatocyte; dosing is twice yearly after the loading doses
Drugs with this mechanism (1)
- Inclisiran — Liver-targeted PCSK9 siRNA for durable LDL lowering in ASCVD and familial hypercholesterolemia.
Self-check
- At what stage does PCSK9 siRNA act?
Hepatic messenger RNA, before the protein is made. - How often is the described PCSK9 siRNA dosed after loading?
Twice yearly.
All mechanisms · Open PCSK9 siRNA in the interactive console ↗